SIZE XSSIZE SMSIZE MDSIZE LG

HOPA BCOP Updates Course 2017

Friday, July 28

Registration Information

                    

Updates in Gastrointestinal Malignancies

Salvatore Bottiglieri, PharmD BCOP

This course will review the management of several key gastrointestinal malignancies including colon and rectal cancer, pancreatic cancer, gastroesophageal cancers, and neuroendocrine tumors. The session will focus on new therapies in each disease state and/or sequencing and optimization of therapies. In addition to introducing updates in each disease state, there will be a focus on medication management and toxicity management, especially in outpatient practice. Case-based learning will be used to apply treatment plans in patients with gastrointestinal malignancies.

Learning Objectives:

  1. Analyze appropriate treatment regimens, toxicity management, and proper sequencing of key therapeutic options in colon cancer.
  2. Differentiate options in the management of adjuvant and metastatic pancreatic cancers and neuroendocrine tumors.
  3. Examine the role of traditional chemotherapy, targeted therapy, and immunotherapy options in gastric and esophageal cancers.

 

                    

Progress and Controversies in the Management of Gynecologic Malignancies

Evelyn Handel, PharmD BCOP BCPS

Slow progress in improving the outcomes of gynecologic malignancies with traditional chemotherapy over the last decade has stimulated research into the potential roles of immunotherapy and molecularly targeted therapy. This presentation will review the impact of recently published data for poly(ADP-ribose) polymerase (PARP) inhibitors, checkpoint inhibitors, and hormonal therapies in gynecologic cancers. In addition, an update on the use of dose-dense versus conventional paclitaxel and a review of other emerging treatment strategies such as trabectedin for gynecologic malignancies will be provided.

Learning Objectives:

  1. Analyze the new developments in targeted, immune-directed, and hormonal therapies for the treatment of advanced gynecologic (GYN) malignancies.
  2. Examine recent data for traditional chemotherapy agents including trabectedin and dose-dense versus conventional paclitaxel for the treatment of GYN cancers.
  3. Consider emerging treatment strategies for gynecologic malignancies and their potential impact on patient outcomes.

 

                    

Updates in the Management of Acute Myeloid Leukemia

Larry Buie, PharmD BCOP FASHP

This session will provide a brief overview of acute myeloid leukemia (AML), with a discussion of patients who may benefit from dose-escalated conventional chemotherapy. Advances in genetic testing will be discussed, and currently approved and investigational targeted therapies will be reviewed.

Learning Objectives:

  1. Utilize molecular profiling to predict prognosis and response in acute myeloid leukemia (AML).
  2. Consider patients that may benefit from dose-escalated conventional or reformulated chemotherapy.
  3. Choose appropriate targeted therapy for use in patients with AML.

 

                    

Updates in Advanced Thyroid Cancer

Milena Wong, PharmD BCOP

This session will review and provide an update of literature for new targeted therapies for use in thyroid cancer. Data regarding efficacy and adverse effects in medullary and non-medullary thyroid cancer will be presented. This data will then be applied to patient cases to help categorize places in therapy for approved targeted agents for the treatment of radioiodine refractory thyroid cancers.

Learning Objectives:

  1. Choose appropriate indication and patient-specific therapy approved targeted therapies for advanced differentiated thyroid cancer and medullary thyroid cancer.
  2. Compare expected outcomes to a given targeted therapy in terms of response and toxicity
  3. Deduce appropriate plans to manage adverse reactions associated with tyrosine kinase inhibitors (TKIs).

 

                    

Updates in Multiple Myeloma

Kathryn Schultz, PharmD BCOP BCPS

This session will review new literature and therapy options for multiple myeloma from the past three years. With increased options for multiple myeloma, data regarding efficacy and adverse effects will be the focus. This data will then be applied to patient cases to help develop a framework for personalization of therapy plans for patients with multiple myeloma.

Learning Objectives:

  1. Interpret data for therapy options in multiple myeloma (MM).
  2. Consider patient specific factors for personalization of multiple myeloma therapy.
  3. Compare adverse effect profiles for therapies used in multiple myeloma.

 

                    

Updates in Hematopoietic Cell Transplantation

Sarah Schmidt, PharmD BCOP BCPS

This session will review key updates from hematopoietic cell transplantation, including alternative donor transplant, use of post-transplant cyclophosphamide in GVHD prevention, maintenance therapy for multiple myeloma and Hodgkin disease, as well as defibrotide use in sinuosoidal obstructive syndrome.

Learning Objectives:

  1. Identify advantages and disadvantages of using alternative donors in HCT.
  2. Explain the use of post-transplant cyclophosphamide (PT/Cy) in graft-versus-host disease (GVHD) prevention.
  3. Interpret recent data on use of defibrotide for sinusoidal obstructive syndrome.

                    

Saturday, July 29

What’s New in CNS Tumors?

Shauna Choi, PharmD BCOP

This session will provide the attendees with a focused update of the 2016 WHO classification of CNS tumors and review the interim analysis with anaplastic oligodendrogliomas in the CODEL trial and with anaplastic astrocytomas in the CATNON trial. Immunotherapy trials with nivolumab or pembrolizumab with or without bevacizumab and the tumor treating field’s research impacting treatment decisions with glioblastoma will also be discussed.

Learning Objectives:

  1. Review the 2016 WHO Classification (revised 4th edition) changes with a focus on tumor markers.
  2. Discuss clinical trials updates in the treatment of both low and high grade gliomas and how they impact current clinical practice.
  3. Report on current immunotherapy research with an appraisal of the treatment challenges in glioblastoma tumors.

 

                    

Updates in Pediatric Malignancies

Joshua Elder, PharmD BCOP BCPS

The treatment of pediatric malignancies is rapidly evolving as immunotherapy and targeted therapies are becoming integrated into treatment plans that historically only utilized conventional chemotherapy. This session will focus on recently published literature highlighting advances in outcomes for pediatric oncology patients. With continuing improvement of outcomes for these pediatric patients with malignancy, an enhanced focus has been placed on the management of long-term side effects. Recent supportive care literature documenting best practices for long-term follow-up care for pediatric oncology patients will also be reviewed.

Learning Objectives:

  1. Explain the utility of asparaginase monitoring in pediatric leukemias.
  2. Review the efficacy and safety of novel agents utilized in the treatment of pediatric malignancies.
  3. Discuss updates in long term outcomes for survivors of pediatric malignancies.

 

                    

Parole Officers for Painkillers

Doreen Pon, PharmD BCOP BCPS

The US has witnessed a 4-fold increase in opioid-related deaths and a 4-fold increase in sales of prescription opioids in the past decade. A number of strategies to help combat this prescription opioid epidemic can be considered. Oncology pharmacists can play a vital role in combating the opioid epidemic and implementing strategies to ensure their patients have appropriate access to opioids, while minimizing the risks for abuse, overdose, and diversion among their patients and in their communities.

Learning Objectives:

  1. Discuss implications of the Centers for Disease Control and Prevention guidelines on the use of opioids for chronic non-cancer pain.
  2. Recommend strategies to help reduce the risk of opioid-related aberrant behaviors and accidental overdose.
  3. Explain recent Food and Drug Administration policy and labeling changes for opioids.

 

                    

Updates in Renal Cell Carcinoma

Kinjal Parikh, PharmD BCOP

This session is intended for beginning and advanced pharmacy practitioners to understand newly approved renal cell carcinoma therapies and apply their use in practice. Discussion will be facilitated through use of clinical trials highlighting design, efficacy, and safety. In addition, clinically important pharmacy pearls will be reviewed. There will also be discussion of new literature regarding current areas of study and future directions in the paradigm of renal cell carcinoma treatment.

Learning Objectives:

  1. Examine the use of nivolumab, cabozantinib, and lenvatinib in the treatment of renal cell carcinoma.
  2. Distinguish efficacy and toxicities of newly approved therapies for renal cell carcinoma.
  3. Explore the emerging data on important questions in renal cell carcinoma: combination therapy, sequencing, and more.
xs
sm
md
lg